Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Alkermes/Reliant end merger

Executive Summary

Alkermes and Reliant are terminating their proposed merger "because of market conditions," CEO Richard Pops tells analysts Aug. 14. The merger, announced March 21, would have given Alkermes the rights to three Reliant products: Lescol, DynaCirc and Axid (1"The Pink Sheet" March 25, In Brief)...

You may also be interested in...



Reliant names CEO

Former Alza CEO Ernest Mario, PhD, named Reliant Pharmaceuticals Chairman and CEO. Mario was most recently CEO of Palo Alto, Calif.-based IntraBiotics; before joining Alza in 1993, Mario was CEO of Glaxo. Reliant post was vacant since Irwin Lerner resigned following termination of proposed merger with Alkermes (1"The Pink Sheet" Aug. 19, 2002, In Brief). Lerner remains on Reliant board...

Alkermes/Reliant merger

Reliant will become a wholly-owned subsidiary of Alkermes following completion of merger announced March 21. Alkermes already owned 18% of the Liberty Corner, New Jersey-based company; it is acquiring the remaining shares through a stock transaction valued at $934 mil. The company will gain rights to three product families through the acquisition: Lescol, DynaCirc and Axid. Reliant's sales and promotional revenue from the products was $277 mil. in 2001...

Moderna Marches First Coronavirus Vaccine To US Test

The first vaccine for the new coronavirus has entered the clinic, with US firm Moderna leading the race.

UsernamePublicRestriction

Register

PS040322

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel